Patents by Inventor Junya Tsuzaki

Junya Tsuzaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combined anticancer drug sensitivity-determining marker
    Patent number: 10481160
    Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: November 19, 2019
    Assignees: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Junya Tsuzaki, Hiroyuki Takahashi
  • COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER
    Publication number: 20170299597
    Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Applicants: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke TANIGAWARA, Akito NISHIMUTA, Junya TSUZAKI, Hiroyuki TAKAHASHI
  • Combined anticancer drug sensitivity-determining marker
    Patent number: 9733256
    Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: August 15, 2017
    Assignees: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Junya Tsuzaki, Hiroyuki Takahashi
  • COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER
    Publication number: 20150038522
    Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Applicants: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Junya Tsuzaki, Hiroyuki Takahashi